David Lockhart
About David Lockhart
David J. Lockhart is a distinguished scientist and executive with extensive experience in biotechnology, particularly in developing technologies and therapies for rare diseases and cancer.
Title and Current Position
David J. Lockhart serves as the President and Chief Scientific Officer. In this role, he spearheads scientific research and strategic leadership, overseeing various program developments and initiatives within the organization.
Education and Expertise
David J. Lockhart holds a Ph.D. in Chemistry from Stanford University, a significant credential that underscores his deep understanding of chemical and biological processes. His postdoctoral fellowship at the Whitehead Institute in the Biology Department at MIT further honed his expertise in biology, laying a solid foundation for his illustrious career in biotechnology.
Career Background
David J. Lockhart's career in biotechnology began at Affymetrix, where he was the primary inventor and developer of gene expression profiling with DNA microarrays. He then served as the Director of Genomics at the Genomics Institute of the Novartis Research Foundation (GNF). He co-founded Ambit Biosciences, serving as Chief Scientific Officer and president for five years, during which he developed novel kinase profiling technology and new kinase inhibitors for cancer and other diseases. He also held the position of Chief Scientific Officer at Amicus Therapeutics from 2006 to 2013, leading a team that brought multiple rare disease programs into clinical trials.
Leadership at TranscripTx
From 2014 to 2020, David J. Lockhart served as CEO and president of TranscripTx. During this period, he led strategic developments and operational management, overseeing the company's growth and the advancement of its scientific programs.
Research Contributions and Patents
David J. Lockhart has made significant contributions to scientific research, with more than 80 peer-reviewed scientific articles published. Additionally, he is an inventor on more than 40 issued U.S. patents, reflecting his role in advancing technological innovations and breakthroughs in the field of biotechnology and medical research.